Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation
Samuel Obiosa Onyekweli, Gloria Osayamen Omoruyi, Christopher Oloruntoba Akintayo, Samuel Kehinde Olaniyi · 2026
Read Engineering CAR-T cells for solid tumors: Overcoming the microenvironment through integrated design and clinical translation by Samuel Obiosa Onyekweli, Gloria Osayamen Omoruyi, Christopher Oloruntoba Akintayo, Samuel Kehinde Olaniyi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13426074.txt.
Description
Samuel Obiosa Onyekweli and coauthors review engineering of CAR-T cells for solid tumors in a 2026 article spanning design and clinical translation. Chimeric antigen receptor therapy excels in blood cancers, yet pooled response rates in solid tumors sit near 9 percent because antigens vary, dense stroma blocks entry, and suppressive surroundings exhaust T cells. Developments in 2024 and 2025 mark a turning point in their account.
GD2-targeted cells delivered into brain ventricles produced durable complete responses in diffuse midline glioma, one lasting beyond 30 months, and CLDN18.2-targeted therapy beat physician's choice in advanced gastric cancer in randomized testing. Integrated design aims to repeat such wins more broadly.
Catalog record
| CREATOR | Samuel Obiosa Onyekweli, Gloria Osayamen Omoruyi, Christopher Oloruntoba Akintayo, Samuel Kehinde Olaniyi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |